ClinicalTrials.gg
RecruitingNCT06615193Updated Sep 26, 2024

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

A Phase 1 interventional study of HDM2005 in Advanced Solid Tumors, Refractory Lymphoma and Relapsed Hematologic Malignancy, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Recruiting at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
111
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 275 studies in Lymphoma with a site in China — 102 open to participants now, 118 under way, 10 of them phase 3. Lymphoma · China.

Planned enrollment
53rd of 232
111 · median 47
Started
2024
with 15 others
Phase 1
83 of 275
25 open now
Primary completion
2026-06
later than 46 of 117 live
Registered
222nd of 275
by date

Among the 275 studies in Lymphoma with a site in China, this one is the 53rd largest by planned enrollment of the 232 interventional ones that give a count, is one of 16 that started in 2024, is one of 83 in phase 1, reaches primary completion later than 46 of the 117 other live ones, and was the 222nd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

102 of the 275 studies in Lymphoma with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.

03

Conditions studied

  • Advanced Solid Tumors
  • Refractory Lymphoma
  • Relapsed Hematologic Malignancy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Agree to follow the study treatment protocol and visit schedule, enroll voluntarily and sign a written ;
  2. Male or female aged ≥ 18 years at the time of signing the ICF;
  3. B-cell lymphoma: performance status of 0-2;
  4. Advanced solid tumors: ECOG performance status of 0-1;
  5. of at least 3 months;
  6. Dose escalation phase: Histopathologically confirmed B-cell lymphoma following at least 2 ;
  7. Dose expansion phase: relapsed/refractory B-cell lymphoma and advanced or solid tumor of specified type.
  8. All subjects are required to provide archived tissue (5 unstained sections) obtained within the previous 2 years or fresh tissue for ROR1 expression testing at the central laboratory; in addition, relapsed/refractory lymphoma subjects are required to provide tissue sections used for previous pathological diagnosis for pathological consultation at the central laboratory;
  9. Relapsed/refractory B-cell lymphoma: Subjects in Phase Ia dose escalation phase should have evaluable lesions; subjects in Phase Ib dose expansion phase should have at least 1 radiographically measurable lymph node or extranodal malignant tumor lesion (intranodal lesion defined as having a long diameter > 1.5 cm; extranodal lesion having a long diameter > 1.0 cm) as assessed by computed tomography (CT)/magnetic resonance imaging (MRI) according to 2014 Lugano criteria, and a lesion that has previously received radiotherapy is considered measurable when it shows unequivocal progression after completion of radiotherapy;
  10. Advanced solid tumors: subjects are required to have at least 1 according to (RECIST) V1.1 ;
  11. Subjects must have recovered (to ≤ Grade 1) from any AE associated with prior anticancer therapy;
  12. Subjects have adequate organ and bone marrow function;
  13. Female subjects of should agree to use methods (e.g., intrauterine device, contraceptive pill, or condom) during the study and for 6 months after the end of the study; have a negative serum pregnancy test within 7 days before study enrollment; and male subjects should agree to use contraceptive avoidance measures during the study and for 6 months after the end of the study.

Exclusion criteria

Exclusion Criteria:

  1. B-cell lymphoma: known central nervous system (CNS) involvement .
  2. Advanced solid tumors: Patients with active (defined as stable for \< 4 weeks, or symptomatic, or requiring antiepileptic drug/hormonal therapy, or meningeal );
  3. Subjects with prior HSCT who have developed acute (GVHD) or persistent evidence of chronic GVHD (as manifested by ≥ Grade 2 serum , ≥ Grade 3 skin involvement, or ≥ Grade 3 diarrhea or receiving systemic therapy/prophylaxis for GVHD);
  4. Subjects have another primary ,with the following exceptions: adequately treated non-melanoma skin cancer without evidence of disease recurrence and adequately treated carcinoma in situ without evidence of disease recurrence,et al;
  5. History of severe bleeding disorders ;
  6. History of chronic pancreatitis or acute pancreatitis within 6 months;
  7. History of interstitial lung disease, radiation pneumonitis requiring therapy, or any evidence of clinically active interstitial lung disease;
  8. Patients with uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage after intubation and drainage, VEGF inhibitors, platinum and other drugs injection (subjects with stable symptoms for at least one week after treatment can be enrolled);
  9. Prior solid organ transplantation;
  10. Persistent peripheral neuropathy > Grade 1 at baseline;
  11. cardiovascular or cerebrovascular diseases;
  12. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection requiring systemic therapy (except for localized skin or nail bed fungal infection) at enrollment;
  13. Active infectious disease, such as infection, active , active (positive RNA result), active syphilis;
  14. Receiving corticosteroids (prednisone equivalent more than 30 mg/day);
  15. to any component of HDM2005;
  16. History of drug anaphylactic shock, severe food allergy, uncontrolled asthma/;
  17. Female subjects who are pregnant, lactating or planning to become pregnant during the study;
  18. Known history of mental illness or substance abuse that would impair the subject's ability to cooperate with study requirements;
  19. Prior or current evidence of any disease, treatment, or laboratory abnormality that, in the opinion of the investigator, could affect the outcome of the study, prevent the subject from participating in the study entirely, or is not in the subjects' best interest.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
111 participants (estimated)

Study arms

  • Experimental
    HDM2005

    In dose escalation phase, participants will be administered escalating doses of HDM2005 at 0.3\~2.75mg/kg IV on Day 1 of repeated 21-day cycles. In dose expansion phase, participants will be administered to recommended dose for expansion (RDE) of HDM2005 on Day 1 of repeated 21-day cycles .

    Drug: HDM2005

Interventions

  • HDM2005 will be administered via IV infusion.

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity (DLT) events (for dose escalation phase)

    DLT will be determined by definition during the DLT observation period.

    Time frame: up to 21 days following first dose

  2. Incident and severity of adverse events(for dose escalation phase)

    The safety profile of HDM2005 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

    Time frame: Until 28 days after the last dose or initiation of a new antineoplastic therapy, whichever occurs first

  3. Objective Response Rate (ORR)(for dose expansion phase)

    Objective response rate (ORR), which includes best response of complete response (CR) or partial response (PR) as assessed by the investigator.

    Time frame: Until withdrawal of consent, loss to follow-up, initiation of other new antineoplastic therapy, end of study, or study termination by the sponsor, whichever occurs first (up to approximately 3.5 years)

  4. Recommended Phase 2 Dose (RP2D) (for dose expansion phase)

    The selection of RP2D will be based on consideration of overall safety information together with available pharmacokinetic,E-R relationships, and efficacy data.

    Time frame: Approximately 3.5 years

Secondary outcomes

  1. Plasma concentration of HDM2005, total antibody and the free MMAE

    Plasma concentration of HDM2005, total antibody and the free MMAE will be reported for each arm.

    Time frame: up to 28 days following last dose

  2. Immunogenicity

    Number and percentage of anti-drug antibody (ADA)-positive patients will be assessed.

    Time frame: up to 28 days following last dose

  3. Incident and severity of adverse events(for dose expansion phase)

    The safety profile of HDM2005 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

    Time frame: Until 28 days after the last dose or initiation of a new antineoplastic therapy, whichever occurs first

  4. Objective Response Rate (ORR)(for dose escalation phase)

    Objective response rate (ORR), which includes best response of complete response (CR) or partial response (PR) as assessed by the investigator.

    Time frame: Approximately 3.5 years

  5. Time to Response (TTR)

    TTR is defined as the interval from the start of study therapy to the first documentation of an objective response.

    Time frame: Approximately 3.5 years

  6. Progression free survival (PFS)

    PFS is defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression/relapse or death from any cause.

    Time frame: Approximately 3.5 years

  7. Duration of Response (DOR)

    DOR is defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression/relapse or death from any cause.

    Time frame: Approximately 3.5 years

  8. Overall survival (OS)

    OS is defined as the interval from the start of study therapy to death from any cause.

    Time frame: Approximately 3.5 years

07

Study locations

4 of 8 sites recruiting
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
    Not yet recruiting
    • Keshu Zhou · Contact
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
    Recruiting
    • Zhengming Jin · Contact
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
    Recruiting
    • Bingzong Li · Contact
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
    Recruiting
    • Zhenyu Li · Contact
  • The First Affiliated Hospital Of Nanchang University
    Nanchang, Jiangxi, China
    Not yet recruiting
    • Fei Li · Contact
  • Shandong Cancer Hospital
    Jinan, Shandong, China
    Not yet recruiting
    • Zengjun Li · Contact
    • Juan Li · Contact
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Not yet recruiting
    • Wenjuan Yu · Contact
  • The Institute of Hematology and Blood Diseases Hospital at the Chinese Academy of Medical Sciences
    Tianjing, China
    Recruiting
    • Lugui Qiu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jun 2026, 22 months after the start.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's planned 22 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2024
First posted
Sep 26, 2024
StartActual
Aug 12, 2024
Primary completionEst.
Jun 24, 2026
CompletionEst.
Feb 1, 2028
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06615193
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Aug 12, 2024
Primary completion
Jun 24, 2026 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Sep 26, 2024

Study contacts

Jun Zhou, Master
Contact
hdgdzhoujun@eastchinapharm.com
18061872796

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM2005

Start the discussion